Disclosure Of Material Accounting Policy Information [Text Block]

OSE Immunotherapeutics - Filing #2813125

Concept 2022-01-01 to
2022-12-31
Disclosure of material accounting policy information [text block]
Description of accounting policy for deferred income tax [text block]
3.18 Impôt
Description of accounting policy for determining components of cash and cash equivalents [text block]
3.9.2 Actifs financiers courants
Description of accounting policy for earnings per share [text block]
3.22 Résultat
Description of accounting policy for financial liabilities [text block]
3.13 Passifs
Description of accounting policy for functional currency [text block]
3.6 Comptes
Description of accounting policy for government grants [text block]
3.14 Aides
Description of accounting policy for impairment of financial assets [text block]
3.8 Test
Description of accounting policy for issued capital [text block]
3.10 Capitau
Description of accounting policy for leases [text block]
3.17 Contrats
Description of accounting policy for loans and receivables [text block]
3.9.1 Actifs financiers non courants
Description of accounting policy for recognition of revenue [text block]
3
Description of accounting policy for research and development expense [text block]
3.7 Immobilisa
Description of accounting policy for segment reporting [text block]
3.20 Informati
Description of accounting policy for taxes other than income tax [text block]
3
Description of accounting policy for treasury shares [text block]
3.11 Actions
Description of accounting policy for warrants [text block]
3.12 Paiements

Talk to a Data Expert

Have a question? We'll get back to you promptly.